Evidence map›Paper›PMID 29670622›Full record

ReviewFrontiers in immunology2018

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators.

Alan Graham Pockley, James O Lindsay, Gemma A Foulds, Sergio Rutella, John G Gribben, Tobias Alexander, John A Snowden

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Stem cell-based therapy for systemic lupus erythematous.Journal of translational autoimmunity · 2024
    Review
  6. Stem cell-based therapy for systemic sclerosis.Rheumatology advances in practice · 2023
    Review
  7. Review
  8. Stem Cell-Based Therapies for Inflammatory Bowel Disease.International journal of molecular sciences · 2022
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Alan Graham PockleyJohn van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
James O LindsayCentre for Immunobiology, Barts and the London School of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, United Kingdom.
Gemma A FouldsJohn van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Sergio RutellaJohn van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
John G GribbenCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Tobias AlexanderDepartment of Rheumatology and Clinical Immunology, Charité - University Medicine, Berlin, Germany.
John A SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Nottingham Trent University · GBQueen Mary University of London · GBGerman Rheumatism Research Centre · DESheffield Teaching Hospitals NHS Foundation Trust · GB

Funding

Chief Scientist OfficeDepartment of Health 15/178/09Department of Health EME/15/178/09Medical Research Council 15/178/09
6 · The paper itself

Abstract

Patients with treatment refractory Crohn's disease (CD) suffer debilitating symptoms, poor quality of life, and reduced work productivity. Surgery to resect inflamed and fibrotic intestine may mandate creation of a stoma and is often declined by patients. Such patients continue to be exposed to medical therapy that is ineffective, often expensive and still associated with a burden of adverse effects. Over the last two decades, autologous hematopoietic stem cell transplantation (auto-HSCT) has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs). Mechanistic studies have provided proof of concept that auto-HSCT can restore immunological tolerance in chronic autoimmunity

Indexed as

Hematopoietic Stem Cell TransplantationAutoimmunityCrohn DiseaseHumansImmune ReconstitutionImmune SystemImmune ToleranceImmunotherapyRandomized Controlled Trials as TopicTransplantation, AutologousTransplantation ConditioningTumor Necrosis Factor-alphaTumor Necrosis Factor-alphaautologous stem cell transplantationCrohn’s diseasehematopoietic stem cell transplantationimmune reconstitutioninflammatory bowel diseasesT cell receptor repertoire

Identifiers

PMID29670622
PMCPMC5893785
OpenAlexW2796319877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.